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. In 2016, our understanding of PBC pathogenesis has been be further refined on the basis of elegant basic and clinical science, including the concept of high-risk and low-risk disease, particularly as recognized after evalu ation of treatment response to the first-line agent ursodeoxycholic acid 2 . Increasingly, it is now recognized that a multistep model of PBC pathogenesis can be identified (FIG. 1) 
. In this setting, therapies for those stratified at high-risk of disease progression despite ursodeoxy cholic acid use will be more or less effective, depending on when they are initiated and how they work 2 . Animal models of PBC have always been a struggle, as attempting to recapitulate such a complex interaction of immunological injury and localized tissue response is challenging. However, work from the Gershwin and Young groups in 2016 has made progress in developing a more meaningful disease model for study, and one that captures the gender distinction seen in PBC 3 . This group studied mice character ized by prolonged chronic expression of IFNγ. Interestingly, in this model, mice developed murine PBC characterized by female predominance, upregulation of total bile acids, spontaneous production of anti-mitochondrial antibodies and portal duct inflammation. Overall, this work highlighted the importance of interferon signalling in initial PBC pathogenesis. Inflammatory responses mediated by type 1 T helper cells have been recognized as critical for loss of immunological tolerance and not only to a response to injury, but also to subsequent signalling pathways leading to chronic inflammatory responses. Thus, the senescenceassociated secretory phenotype of biliary epithelial cells might be relevant in PBC and other cholestatic liver diseases, and changes in AE2 function could be a 'bridge' between the immune system and cholestasis. Additionally, that IL-17-positive T cells are detected in portal infiltrates close to inflamed bile ducts expressing the CCR6 ligand CCL20 is already known 7 . Cytokine-treated human cholangiocytes secrete CCL20 and induce CCR6-dependent migration of type 17 T helper cells, suggesting that local cholangiocyte chemokine secretion then localises these pathogenic and damaging cells to bile ducts 7 . Intriguingly, CCL20 is a recognized genetic risk locus for PBC development and could be a meaningful added target for intervention 4 . Further advances in understanding the careful orchestration of liver injury have come from better appreciation of the gutliver axis, with focus towards the farnesoid X receptor (FXR)-fibroblast growth factor (FGF)-19 signalling pathway. FXR is a central transcriptional sensor of bile acid metabolism and one key target gene in the gut is FGF19, which encodes an enterokine released into portal blood following bile acid binding to FXR. Augmentation of this pathway presents opportunities for therapeutic benefit, with the this data parallels an understanding of PBC genetic risk that spans key immune-regulatory pathways including IL-12 and JAK-STAT signalling 4 , pathways potentially additionally modifiable by oestrogen exposure.
A dichotomous understanding of PBC has often been raised between the importance of immunological injury alongside cellular response to biliary injury and cholestasis. With more sophisticated experimental approaches, it seems that this distinction is beginning to blur and in a way that might indicate better therapeutic approaches. Notably, it has become relevant that the Cl − /HCO 3 -exchanger (AE2; anion exchanger 2) and an intact biliary glyco calyx are important in maintaining a protective biliary HCO 3 − 'umbrella' . In 2016, Chang et al. 5 explored this understanding, demonstrating in vitro that soluble adenylyl cyclase, a bicarbo nate sensor, regulates bilesalt-induced apoptosis in a manner dependent on intracellular Ca 2+ stores, which are mediated by intrinsic apoptotic pathways. These findings suggest that downregulation of AE2 in PBC can sensitize cholangiocytes to apoptotic insults by activating soluble adenylyl cyclase. Intriguingly, in related work, Hisamoto et al. 6 found that hydrophobic bile acids (glycochenodeoxycholic acid) suppress expression of AE2 in biliary epithelial cells by inducing reactive oxygen species and enhancing biliary epithelial cell senescence, which induced bile duct inflammation. Reduced AE2 expression also upregulated the expression of CD40 and HLA-DR, as well as production of IL-6, IL-8 and CXCL10 from biliary epithelial cells in response to Toll-like receptor ligands (CXCL10 is secreted in response to IFNγ). This work equally highlights how changes to normal bili ary epithelial cell physiology are relevant, High-definition PBC: biology, models and therapeutic advances
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In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.
Key advances
• Overexpression of the IFNγ pathway in mice led to an animal model of autoimmune cholangitis that recapitulates the female preponderance of primary biliary cholangitis (PBC) 3 • Bile-salt-induced apoptosis is regulated by soluble adenylyl cyclase; dysregulation of anion exchanger 2 function sensitizes biliary cells to apoptosis by activating soluble adenylyl cyclase 5 • Glycochenodeoxycholic acid reduces expression of anion exchanger 2 in biliary epithelial cells, inducing reactive oxygen species and enhancing epithelial cell senescence 6 • A clinical trial supports the efficacy of obeticholic acid in the treatment of patients failing current care 10 , leading to a licensed therapeutic that is predicted to change the clinical course of PBC goal of directing enhanced anti-inflammatory, anti-fibrotic and anti-cholestatic mechanisms. In the liver, FGF19 regulates intracellular pathways inhibiting CYP7A1, the rate-limiting enzyme in bile acid synthesis 8 . An FGF19 variant (M70) has been developed as a potential new therapeutic for cholestatic liver diseases, which constitutively inhibits synthesis and hepatic accumulation of bile acids, without carcinogenic potential 8 . In 2016, Zhou et al. 9 showed that modulation of bile acid metabolism with FGF19 or M70 in a mouse model of cholangiopathy effectively reversed liver injury, decreased hepatic inflammation and reduced biliary fibrosis. These effects seemed contingent on inhibition of hepatic expression of CYP7A1 and CYP27A1, genes encoding key enzymes in the classic and alternate bile acid synthesis pathways. This approach is now undergoing clinical trials spanning cholestatic liver diseases and NAFLD.
Finally, convincing data have emerged over the past 5 years supporting clinical efficacy for a semisynthetic FXR agonist, obeticholic acid, such that 2016 culminated in a new internationally approved therapy for patients with PBC. In particular, data published in 2016 from a large clinical trial with obeticholic acid 10 added to previous studies showing that FXR agonism has clear, durable effects on relevant markers of active cholestatic liver injury. Obeticholic acid reduces exposure to toxic hydrophobic bile acids by predicted and demonstrated falls in bile acid synthesis through direct and indirect (FGF19) actions on CYP7A1-mediated bile acid synthesis, as well as bile acid excretion by hepatocytes. In conjunction with considerable work on surrogate markers of PBC disease course and outcome, the data from the obeticholic acid trials proved sufficient for product authorisation. Patients with PBC now have access to the first of, hopefully, many new generation treatments for their disease, which have arisen from collective ongoing efforts to finally understand PBC in high-definition. HLA-DR CD40
